Myria Biosciences Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Early Stage VC
- Investors
-
6
Myria Biosciences General Information
Description
Developer of therapeutic molecules designed to transform drug discovery with synthetic intelligence. The company's technology recombines modular Deoxyribonucleic acid (DNA) elements derived from natural products into functional new-to-nature molecules for pharmaceutical and biotechnology applications and leverages synthetic biology, artificial intelligence, biological high-throughput screening to access new chemical space and engineer complex molecule drugs to tackle previously undruggable targets, enabling medical professionals to get natural product drugs for unmet medical needs.
Contact Information
Website
www.myria.bioCorporate Office
- Hochbergerstrasse 60C
- 4057 Basel
- Switzerland
Corporate Office
- Hochbergerstrasse 60C
- 4057 Basel
- Switzerland
Myria Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | Completed | Startup | ||||
| 1. Seed Round | 21-Jun-2024 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Myria Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Myria Biosciences Patents
Myria Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4424820-A1 | Designed synzip protein domains for generating artificial nonribosomal peptide synthetases and hybrids thereof | Pending | 03-Mar-2023 | ||
| WO-2024184317-A1 | Designed synzip protein domains for generating artificial nonribosomal peptide synthetases and hybrids thereof | Inactive | 03-Mar-2023 |
Myria Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Myria Biosciences Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BeAI | Venture Capital | Minority | ||
| Capital Blue Partners | Family Office | Minority | ||
| Creator Fund | Venture Capital | Minority | ||
| Rockmount Seed Investments | Corporate Venture Capital | Minority | ||
| Mosel Ventures | Venture Capital | Minority |
Myria Biosciences FAQs
-
When was Myria Biosciences founded?
Myria Biosciences was founded in 2022.
-
Where is Myria Biosciences headquartered?
Myria Biosciences is headquartered in Basel, Switzerland.
-
What is the size of Myria Biosciences?
Myria Biosciences has 7 total employees.
-
What industry is Myria Biosciences in?
Myria Biosciences’s primary industry is Drug Discovery.
-
Is Myria Biosciences a private or public company?
Myria Biosciences is a Private company.
-
What is Myria Biosciences’s current revenue?
The current revenue for Myria Biosciences is .
-
Who are Myria Biosciences’s investors?
BeAI, Capital Blue Partners, Creator Fund, Rockmount Seed Investments, and Mosel Ventures are 5 of 6 investors who have invested in Myria Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
